SynthesisAnnals of medicine2024
Incidence and risk factors of VTE in lung cancer: a meta-analysis.
Synthesis in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-bacterial Thrombotic Endocarditis in Lung Cancer: A Systematic Review.Current cardiology reviews · 2025Pooled it
- Phlegmasia Cerulea Dolens and Pulmonary Embolism in a Patient With NSCLC Receiving Dual EGFR/MET Targeted Therapy: A Case Report.JTO clinical and research reports · 2026Article
- MOF promotes venous thromboembolism in lung cancer by activating the YBX1-MALT1-NF-κB-PAI-1 axis, possibly through histone crotonylation.The Journal of biological chemistry · 2026Article
- Role of Troponins in CardioOncology.Current treatment options in oncology · 2026Review
- An Immunothrombotic Extracellular Vesicle mRNA Profile Associated with Thrombosis in Lung Adenocarcinoma.International journal of molecular sciences · 2026Article
- Risk Factors for Developing Venous Thromboembolism in Patients With Advanced ALK-Rearranged NSCLC.JTO clinical and research reports · 2026Article
- Trends in pulmonary embolism mortality among older adults with lung cancer in the united States, 1999-2020.Journal of thrombosis and thrombolysis · 2026Article
- Incidence and risk factors for catheter-related thrombosis in elderly patients with malignant tumors: a single-center retrospective cohort study.Frontiers in oncology · 2026Article
- Incidence and Predictors of Pulmonary Embolism Recurrence and Mortality in Patients With Lung Cancers.Cureus · 2025Article
- The incidence and risk factors of venous thromboembolism in patients with pancreatic cancer: a systematic review and meta-analysis.Journal of gastrointestinal oncology · 2025Article
- Assessing venous thromboembolism risk in lung cancer: a comprehensive evaluation of the khorana score, clinical characteristics, and incidence of thrombosis.Frontiers in oncology · 2025Article
- Sex-specific Risks in Lung Cancer-Associated Thrombosis: Focus on Female Patients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
- [Highlights of the 58th Congress of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)].Open respiratory archivesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer has maintained a high prevalence and mortality. Besides, venous thromboembolism (VTE) is the third most common disease of cardiovascular disease. Lung cancer with VTE usually influenced the overall survival in the follow-up. In the development of lung cancer, vigilance against and early diagnosis of VTE is of significance.
methodsWe searched the databases of PubMed, Web of Science, Embase and Cochrane for related research up to 30 November 2023 and extracted information of incidence, odds ratio (OR), hazard ratio (HR) and their 95% confidence intervals (CIs), for evaluating the incidence of VTE and its risk factors.
resultsA total of 54 articles and 873,292 records were included in our study. The pooled incidences of VTE and PE were 6% and 3%, respectively. Subgroup analysis revealed that the tumour, node and metastasis (TNM) stage (HR= 5.43, 95% CI: 2.42, 12.22), metastasis (HR= 2.67, 95% CI: 1.35, 5.29) and chemotherapy (HR= 2.27, 95% CI: 1.11, 4.65) had major influence on VTE occurrence.
conclusionsLung cancer complicated with VTE is unignorable, and its occurrence varies widely by tumour staging, tissue type and treatment. The results may aid in clinical decision-making about lung cancer in higher risk with VTE and weather receiving anticoagulant prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.